Methodology and scope
1 Profiles of coming off-patent herbicides
1.1 Flucetosulfuron
1.2 Flufenpyr-ethyl
1.3 Foramsulfuron
1.4 Metamifop
1.5 Orthosulfamuron
1.6 Penoxsulam
1.7 Pinoxaden
1.8 Propoxycarbazone
1.9 Tembotrione
1.10 Thiencarbazone-methyl
1.11 Topramezone
2 Profiles of coming off-patent insecticides
2.1 Bistrifluron
2.2 Clothianidin
2.3 Ethiprole
2.4 Flubendiamide
2.5 Metofluthrin
2.6 Pyridalyl
2.7 Pyrifluquinazon
2.8 Spirotetramat
3 Profiles of coming off-patent fungicides
3.1 Amisulbrom
3.2 Benalaxyl-M
3.3 Benthiavalicarb-isopropyl
3.4 Cyflufenamid
3.5 Dimoxystrobin
3.6 Fluopicolide
3.7 Fluoxastrobin
3.8 Isotianil
3.9 Metalaxyl-M
3.10 Metrafenone
3.11 Orysastrobin
3.12 Penthiopyrad
3.13 Prothioconazole
3.14 Pyraclostrobin
3.15 Silthiofam
3.16 Valifenalate
LIST OF TABLES
Table 1.1-1 Patent information of flucetosulfuron in some countries/regions, as of April 2015
Table 1.1-2 Registration information of flucetosulfuron in China, as of April 2015
Table 1.2-1 Patent information of flufenpyr-ethyl in some countries/regions, as of April 2015
Table 1.3-1 Patent information of foramsulfuron in some countries/regions, as of April 2015
Table 1.3-2 Registration information of foramsulfuron in Argentina, as of April 2015
Table 1.3-3 Registration information of foramsulfuron in Australia, as of April 2015
Table 1.3-4 Registration information of foramsulfuron in Belgium, as of April 2015
Table 1.3-5 Registration information of foramsulfuron in Canada, as of April 2015
Table 1.3-6 Registration information of foramsulfuron in Chile, as of April 2015
Table 1.3-7 Registration information of foramsulfuron in Denmark, as of April 2015
Table 1.3-8 Registration information of foramsulfuron in France, as of April 2015
Table 1.3-9 Registration information of foramsulfuron in Greece, as of April 2015
Table 1.3-10 Registration information of foramsulfuron in the Netherlands, as of April 2015
Table 1.3-11 Registration information of foramsulfuron in Switzerland, as of April 2015
Table 1.3-12 Registration information of foramsulfuron in Uruguay, as of April 2015
Table 1.4-1 Patent information of metamifop in some countries/regions, as of April 2015
Table 1.4-2 Registration information of metamifop in China, as of April 2015
Table 1.5-1 Patent information of orthosulfamuron in some countries/regions, as of April 2015
Table 1.5-2 Registration information of orthosulfamuron in Brazil, as of April 2015
Table 1.5-3 Registration information of orthosulfamuron in China, as of April 2015
Table 1.6-1 Patent information of penoxsulam in some countries/regions, as of April 2015
Table 1.6-2 Registration information of penoxsulam in Argentina, as of April 2015
Table 1.6-3 Registration information of penoxsulam in Brazil, as of April 2015
Table 1.6-4 Registration information of penoxsulam in Chile, as of April 2015
Table 1.6-5 Registration information of penoxsulam in China, as of April 2015
Table 1.6-6 Registration information of penoxsulam in France, as of April 2015
Table 1.6-7 Registration information of penoxsulam in Greece, as of April 2015
Table 1.6-8 Registration information of penoxsulam in Switzerlands, as of April 2015
Table 1.6-9 Registration information of penoxsulam in Uruguay, as of April 2015
Table 1.7-1 Patent information of pinoxaden in some countries/regions, as of April 2015
Table 1.7-2 Registration information of pinoxaden in Argentina, as of April 2015
Table 1.7-3 Registration information of pinoxaden in Australia, as of April 2015
Table 1.7-4 Registration information of pinoxaden in Belgium, as of April 2015
Table 1.7-5 Registration information of pinoxaden in Canada, as of April 2015
Table 1.7-6 Registration information of pinoxaden in Chile, as of April 2015
Table 1.7-7 Registration information of pinoxaden in China, as of April 2015
Table 1.7-8 Registration information of pinoxaden in Finland, as of April 2015
Table 1.7-9 Registration information of pinoxaden in France, as of April 2015
Table 1.7-10 Registration iunformation of pinoxaden in Greece, as of April 2015
Table 1.7-11 Registration information of pinoxaden in the Netherlands, as of April 2015
Table 1.7-12 Registration information of pinoxaden in Switzerland, as of April 2015
Table 1.7-13 Registration information of pinoxaden in Uruguay, as of April 2015
Table 1.8-1 Patent information of propoxycarbazone in some countries/regions, as of April 2015
Table 1.8-2 Registration information of propoxycarbazone in Belgium, as of April 2015
Table 1.8-3 Registration information of propoxycarbazone in Finland, as of April 2015
Table 1.8-4 Registration information of propoxycarbazone in France, as of April 2015
Table 1.8-5 Registration information of propoxycarbazone in Greece, as of April 2015
Table 1.9-1 Patent information of tembotrione in some countries/regions, as of April 2015
Table 1.9-2 Registration information of tembotrione in Belgium, as of April 2015
Table 1.9-3 Registration information of tembotrione in Canada, as of April 2015
Table 1.9-4 Registration information of tembotrione in Chile, as of April 2015
Table 1.9-5 Registration information of tembotrione in France, as of April 2015
Table 1.9-6 Registration information of tembotrione in Greece, as of April 2015
Table 1.9-7 Registration information of tembotrione in the Netherlands, as of April 2015
Table 1.9-8 Registration information of tembotrione in Switzerland, as of April 2015
Table 1.10-1 Patent information of thiencarbazone-methyl in some countries/regions, as of April 2015
Table 1.10-2 Registration information of thiencarbazone-methyl in Belgium, as of April 2015
Table 1.10-3 Registration information of thiencarbazone-methyl in Canada, as of April 2015
Table 1.10-4 Registration information of thiencarbazone-methyl in France, as of April 2015
Table 1.10-5 Registration information of thiencarbazone-methyl in Greece, as of April 2015
Table 1.10-6 Registration information of thiencarbazone-methyl in Switzerland, as of April 2015
Table 1.11-1 Patent information of topramezone in some countries/regions, as of April 2015
Table 1.11-2 Registration information of topramezone in Argentina, as of April 2015
Table 1.11-3 Registration information of topramezone in Belgium, as of April 2015
Table 1.11-4 Registration information of topramezone in Canada, as of April 2015
Table 1.11-5 Registration information of topramezone in Chile, as of April 2015
Table 1.11-6 Registration information of topramezone in China, as of April 2015
Table 1.11-7 Registration information of topramezone in Greece, as of April 2015
Table 1.11-8 Registration information of topramezone in the Netherlands, as of April 2015
Table 2.1-1 Patent information of bistrifluron in some countries/regions, as of April 2015
Table 2.1-2 Registration information of bistrifluron in Australia, as of April 2015
Table 2.2-1 Patent information of clothianidin in some countries/regions, as of April 2015
Table 2.2-2 Registration information of clothianidin in Argentina, as of April 2015
Table 2.2-3 Registration information of clothianidin in Australia, as of April 2015
Table 2.2-4 Registration information of clothianidin in Belgium, as of April 2015
Table 2.2-5 Registration information of clothianidin in Brazil, as of April 2015
Table 2.2-6 Registration information of clothianidin in Canada, as of April 2015
Table 2.2-7 Registration information of clothianidin in China, as of April 2015
Table 2.2-8 Registration information of clothianidin in Finland, as of April 2015
Table 2.2-9 Registration information of clothianidin in Greece, as of April 2015
Table 2.2-10 Registration information of clothianidin in the Netherlands, as of April 2015
Table 2.2-11 Registration information of clothianidin in Switzerland, as of April 2015
Table 2.2-12 Registration information of clothianidin in Uruguay, as of April 2015
Table 2.3-1 Patent information of ethiprole in some countries/regions, as of April 2015
Table 2.3-2 Registration information of ethiprole in China, as of April 2015
Table 2.4-1 Patent information of flubendiamide in some countries/regions, as of April 2015
Table 2.4-2 Registration information of flubendiamide in Australia as of April 2015
Table 2.4-3 Registration information of flubendiamide in Chile as of April 2015
Table 2.4-4 Registration information of flubendiamide in China, as of April 2015
Table 2.4-5 Registration information of flubendiamide in Greece as of April 2015
Table 2.4-6 Registration information of flubendiamide in the Netherlands as of April 2015
Table 2.4-7 Registration information of flubendiamide in Uruguay as of April 2015
Table 2.5-1 Patent information of metofluthrin in some countries/regions, as of April 2015
Table 2.5-2 Registration information of metofluthrin in Australia, as of April 2015
Table 2.5-3 Registration information of metofluthrin in Canada, as of April 2015
Table 2.5-4 Registration information of metofluthrin in China, as of April 2015
Table 2.5-5 Registration information of metofluthrin in the Netherlands, as of April 2015
Table 2.6-1 Patent information of pyridalyl in some countries/regions, as of April 2015
Table 2.6-2 Registration information of pyridalyl in China, as of April 2015
Table 2.6-3 Registration information of pyridalyl in the Netherlands, as of April 2015
Table 2.7-1 Patent information of pyrifluquinazon in some countries/regions, as of April 2015
Table 2.8-1 Patent information of spirotetramat in some countries/regions, as of April 2015
Table 2.8-2 Registration information of spirotetramat in Australia, as of April 2015
Table 2.8-3 Registration information of spirotetramat in Belgium, as of April 2015
Table 2.8-4 Registration information of spirotetramat in Canada, as of April 2015
Table 2.8-5 Registration information of spirotetramat in Chile, as of April 2015
Table 2.8-6 Registration information of spirotetramat in China, as of April 2015
Table 2.8-7 Registration information of spirotetramat in France, as of April 2015
Table 2.8-8 Registration information of spirotetramat in Greece, as of April 2015
Table 2.8-9 Registration information of spirotetramat in the Netherlands, as of April 2015
Table 2.8-10 Registration information of spirotetramat in Switzerland, as of April 2015
Table 3.1-1 Patent information of amisulbrom in some countries/regions, as of April 2015
Table 3.1-2 Registration information of amisulbrom in Belgium, as of April 2015
Table 3.1-3 Registration information of amisulbrom in Finland, as of April 2015
Table 3.1-4 Registration information of amisulbrom in the Netherlands, as of April 2015
Table 3.1-5 Registration information of amisulbrom in Switzerland, as of April 2015
Table 3.2-1 Patent information of benalaxyl-M in some countries/regions, as of April 2015
Table 3.2-2 Registration information of benalaxyl-M in Australia, as of April 2015
Table 3.2-3 Registration information of benalaxyl-M in Belgium, as of April 2015
Table 3.2-4 Registration information of benalaxyl-M in Brazil, as of April 2015
Table 3.2-5 Registration information of benalaxyl-M in Chile, as of April 2015
Table 3.2-6 Registration information of benalaxyl-M in France, as of April 2015
Table 3.2-7 Registration information of benalaxyl-M in Greece , as of April 2015
Table 3.2-8 Registration information of benalaxyl-M in the Netherlands, as of April 2015
Table 3.2-9 Registration information of benalaxyl-M in Switzerland, as of April 2015
Table 3.3-1 Patent information of benthiavalicarb-isopropyl in some countries/regions, as of April 2015
Table 3.3-2 Registration information of Benthiavalicarb-isopropyl in Belgium, as of April 2015
Table 3.3-3 Registration information of Benthiavalicarb-isopropyl in Greece, as of April 2015
Table 3.3-4 Registration information of Benthiavalicarb-isopropyl in the Netherlands, as of April 2015
Table 3.3-5 Registration information of Benthiavalicarb-isopropyl in Switzerland, as of April 2015
Table 3.4-1 Patent information of cyflufenamid in some countries/regions, as of April 2015
Table 3.4-2 Registration information of cyflufenamid in Australia, as of April 2015
Table 3.4-3 Registration information of cyflufenamid in Belgium, as of April 2015
Table 3.4-4 Registration information of cyflufenamid in Greece, as of April 2015
Table 3.4-5 Registration information of cyflufenamid in the Netherlands, as of April 2015
Table 3.4-6 Registration information of cyflufenamid in Switzerland, as of April 2015
Table 3.5-1 Patent information of dimoxystrobin in some countries/regions, as of April 2015
Table 3.5-2 Registration information of dimoxystrobin in Belgium, as of April 2015
Table 3.5-3 Registration information of dimoxystrobin in Denmark, as of April 2015
Table 3.5-4 Registration information of dimoxystrobin in France, as of April 2015
Table 3.6-1 Patent information of fluopicolide in some countries/regions, as of April 2015
Table 3.6-2 Registration information of fluopicolide in Argentina, as of April 2015
Table 3.6-3 Registration information of fluopicolide in Belgium, as of April 2015
Table 3.6-4 Registration information of fluopicolide in Brazil, as of April 2015
Table 3.6-5 Registration information of fluopicolide in Canada, as of April 2015
Table 3.6-6 Registration information of fluopicolide in Chile, as of April 2015
Table 3.6-7 Registration information of fluopicolide in China, as of April 2015
Table 3.6-8 Registration information of fluopicolide in Finland, as of April 2015
Table 3.6-9 Registration information of fluopicolide in France, as of April 2015
Table 3.6-10 Registration information of fluopicolide in Greece, as of April 2015
Table 3.6-11 Registration information of fluopicolide in the Netherlands, as of April 2015
Table 3.6-12 Registration infromation of fluopicolide in Switzerland, as of April 2015
Table 3.6-13 Registration information of fluopicolide in Uruguay, as of April 2015
Table 3.7-1 Patent information of fluoxastrobin in some countries/regions, as of April 2015
Table 3.7-2 Registration information of fluoxastrobin in Argentina, as of April 2015
Table 3.7-3 Registration information of fluoxastrobin in Belgium, as of April 2015
Table 3.7-4 Registration information of fluoxastrobin in Canada, as of April 2015
Table 3.7-5 Registration information of fluoxastrobin in France, as of April 2015
Table 3.7-6 Registration information of fluoxastrobin in the Netherlands, as of April 2015
Table 3.7-7 Registration information of fluoxastrobin in Switzerland, as of April 2015
Table 3.7-8 Registration information of fluoxastrobin in Uruguay, as of April 2015
Table 3.8-1 Patent information of isotianil in some countries/regions, as of April 2015
Table 3.9-1 Patent information of metalaxyl-M in some countries/regions, as of April 2015
Table 3.9-2 Registration information of metalaxyl-M in Australia, as of April 2015
Table 3.9-3 Registration information of metalaxyl-M in Belgium, as of April 2015
Table 3.9-4 Registration information of metalaxyl-M in Brazil, as of April 2015
Table 3.9-5 Registration information of metalaxyl-M in Canada, as of April 2015
Table 3.9-6 Registration information of metalaxyl-M in China, as of April 2015
Table 3.9-7 Registration information of metalaxyl-M in Finland, as of April 2015
Table 3.9-8 Registration information of metalaxyl-M in Greece, as of April 2015
Table 3.9-9 Registration information of metalaxyl-M in the Netherlands, as of April 2015
Table 3.9-10 Registration information of metalaxyl-M in South Africa, as of April 2015
Table 3.9-11 Registration information of metalaxyl-M in Switzerland, as of April 2015
Table 3.10-1 Patent information of metrafenone in some countries/regions, as of April 2015
Table 3.10-2 Registration information of metrafenone in Australia, as of April 2015
Table 3.10-3 Registration information of metrafenone in Belgium, as of April 2015
Table 3.10-4 Registration information of metrafenone in Canada, as of April 2015
Table 3.10-5 Registration information of metrafenone in Chile, as of April 2015
Table 3.10-6 Registration information of metrafenone in France, as of April 2015
Table 3.10-7 Registration information of metrafenone in Greece, as of April 2015
Table 3.10-8 Registration information of metrafenone in Switzerland, as of April 2015
Table 3.11-1 Patent information of orysastrobin in some countries/regions, as of April 2015
Table 3.12-1 Patent information of penthiopyrad in some countries/regions, as of April 2015
Table 3.12-2 Registration information of penthiopyrad in Australia, as of April 2015
Table 3.12-3 Registration information of penthiopyrad in France, as of April 2015
Table 3.13-1 Patent information of prothioconazole in some countries/regions, as of April 2015
Table 3.13-2 Registration information of prothioconazole in Argentina, as of April 2015
Table 3.13-3 Registration information of prothioconazole in Australia, as of April 2015
Table 3.13-4 Registration information of prothioconazole in Brazil, as of April 2015
Table 3.13-5 Registration information of prothioconazole in Canada, as of April 2015
Table 3.13-6 Registration information of prothioconazole in Finland, as of April 2015
Table 3.13-7 Registration information of prothioconazole in France, as of April 2015
Table 3.13-8 Registration information of prothioconazole in Greece, as of April 2015
Table 3.13-9 Registration information of prothioconazole in Switzerland, as of April 2015
Table 3.14-1 Patent information of pyraclostrobin in some countries/regions, as of April 2015
Table 3.14-2 Registration information of pyraclostrobin in Argentina, as of April 2015
Table 3.14-3 Registration information of pyraclostrobin in Australia, as of April 2015
Table 3.14-4 Registration information of pyraclostrobin in Belgium, as of April 2015
Table 3.14-5 Registration information of pyraclostrobin in Canada, as of April 2015
Table 3.14-6 Registration information of pyraclostrobin in China, as of April 2015
Table 3.14-7 Registration information of pyraclostrobin in Denmark, as of April 2015
Table 3.14-8 Registration information of pyraclostrobin in Finland, as of April 2015
Table 3.14-9 Registration information of pyraclostrobin in France, as of April 2015
Table 3.14-10 Registration information of pyraclostrobin in Greece, as of April 2015
Table 3.14-11 Registration information of pyraclostrobin in the Netherlands, as of April 2015
Table 3.14-12 Registration information of pyraclostrobin in South Africa, as of April 2015
Table 3.14-13 Registration information of pyraclostrobin in Switzerland, as of April 2015
Table 3.14-14 Registration information of pyraclostrobin in Uruguay, as of April 2015
Table 3.15-1 Patent information of silthiofam in some countries/regions, as of April 2015
Table 3.15-2 Registration information of silthiofam in Belgium, as of April 2015
Table 3.15-3 Registration information of silthiofam in China, as of April 2015
Table 3.15-4 Registration information of silthiofam in Denmark, as of April 2015
Table 3.15-5 Registration information of silthiofam in France, as of April 2015
Table 3.16-1 Patent information of valifenalate in some countries/regions, as of April 2015
Table 3.16-2 Registration information of valifenalate in Belgium, as of April 2015
Table 3.16-3 Registration information of valifenalate in France, as of April 2015
Table 3.16-4 Registration information of valifenalate in Switzerland, as of April 2015